Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions.
Saved in:
| Title: | Significance of gut breast cancer resistance protein versus organic anion transporting polypeptide 2B1 inhibition on rosuvastatin clinical drug-drug interactions. |
|---|---|
| Authors: | West MA; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Research and Development, Pfizer Inc., Groton, Connecticut., Lazzaro S; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Research and Development, Pfizer Inc., Groton, Connecticut., Morrow R; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Research and Development, Pfizer Inc., Groton, Connecticut., Costales C; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Research and Development, Pfizer Inc., Groton, Connecticut., Yee SW; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Research and Development, Pfizer Inc., Groton, Connecticut., Varma MVS; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Research and Development, Pfizer Inc., Groton, Connecticut. Electronic address: manthena.v.varma@pfizer.com. |
| Source: | Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2025 Apr; Vol. 53 (4), pp. 100056. Date of Electronic Publication: 2025 Mar 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: Netherlands NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1521-009X |
|---|---|
| DOI: | 10.1016/j.dmd.2025.100056 |
